Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents
FDA Law Blog
JUNE 13, 2024
FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. The Court addressed Teva’s valid argument that the Inhaler Patents are drug product patents and thus listable. that is described in the pending or approved NDA ” (emphasis added).
115 
Let's personalize your content